52 Chapter 2 Supplement 2 - (continued) First author Year Country N Disease group Age (min) Age (max) Used method* Setting Laster [151] 2009 United States 19 Asthma 8 17 2 Clinical care Leite [152] 2019 Brazil 16 Multiple disease groups 7 12 1 Clinical care Lewis [153] 2013 United Kingdom 30 Epilepsy 13 19 1,2 Clinical care Lindeke [154] 2006 United States 120 Hospital admission 4 20 7 Clinical care Linder [155] 2021 United States 19 Oncology 6 12 1 Intervention development Lindstrom Nilsson [156] 2019 Sweden 50 Multiple disease groups 3 18 1 Clinical care Linge [157] 2012 Sweden 9 Multiple disease groups 2 18 1 Clinical care Lipstein [158] 2013 United States 15 Multiple disease groups 11 18 1 Clinical care Livesley [159] 2013 United Kingdom 15 Kidney diseases 5 15 5 Clinical care Lock [160] 2010 United Kingdom 12 Ear, nose and throat disorders 4 16 1 Clinical care Lööf [161] 2019 Sweden 22 Surgery 4 15 1 Clinical care Lopez-Vargas [162] 2018 Australia 3 Multiple disease groups 8 14 2 Research Loureiro [163] 2020 Portugal 252 Hospital admission 7 11 5 Clinical care Luchtenberg [164] 2015 United Kingdom 25 Multiple disease groups 10 23 1 Research Luchtenberg [165] 2020 United Kingdom / The Netherlands 52 Multiple disease groups 9 18 1 Research Luseno [166] 2017 Kenya 29 Human Immunodeficiency Virus 15 19 1 Clinical care Macartney [167] 2014 Canada 12 Oncology 9 18 1 Clinical care Mansson [168] 2013 Sweden 12 Multiple disease groups 5 10 1 Clinical care Mant [169] 2019 United Kingdom 6 Oncology 8 12 1 Clinical care Marcinowicz [170] 2016 Poland 22 Multiple disease groups 10 16 1 Clinical care Mari Ruberg Ekra [171] 2012 Norway 9 Diabetes 7 12 1,4 Clinical care Martin-Kerry [172] 2019 United Kingdom 21 Multiple disease groups 6 19 1,2 Research McCann [173] 2014 United Kingdom 12 Oncology 17 25 1 Clinical care McDonald [174] 2006 United Kingdom 63 Hospital admission 2 15 3 Clinical care
RkJQdWJsaXNoZXIy MTk4NDMw